Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants

Jonsson Comprehensive Cancer Center

Status

Terminated

Conditions

Lung Cancer

Treatments

Procedure: fluorine F 18 FEQA + positron emission tomography

Study type

Interventional

Funder types

Other

Identifiers

NCT00444223

UCLA-0304039-01

CDR0000529363

Details and patient eligibility

About

RATIONALE: Fluorine F 18 FEQA may be an effective radioactive drug to use with positron emission tomography (PET) scans.

PURPOSE: This clinical trial is studying the use of fluorine F 18 FEQA in patients with stage III or stage IV non-small cell lung cancer and in healthy participants.

Full description

OBJECTIVES:

Determine the biodistribution of fluorine F 18 FEQA in patients with stage III or IV non-small cell lung cancer (NSCLC) and in healthy participants.
Determine whether fluorine F 18 FEQA can be used as an imaging agent with positron emission tomography in patients with stage III or IV NSCLC.

OUTLINE: This is a pilot study.

Patients and healthy participants receive fluorine F 18 FEQA IV and then undergo whole-body dynamic scans comprising positron emission tomography.

Blood is collected during and after imaging to measure radioactivity.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Enrollment

3 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Must meet 1 of the following criteria:
Diagnosis of non-small cell lung cancer by CT scan, bone scan, or biopsy
- Stage III or IV disease
- Clinically assessed with
Healthy participant

Exclusion Criteria: